Inhibiting Metastatic Breast Cancer Cell Migration via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine Axis Blockade

Molecular Pharmaceutics

Volumn 11, Issue 3, 2014, Pages 755-765

  Guo, Peng ^a,b,c   You, Jin Oh ^d   Yang, Jiang ^b,c   Jia, Di ^b,c   Moses, Marsha A ^b,c   Auguste, Debra T ^a,b,c  

^a City University of New York   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Chungbuk National University   (South Korea)

Author keywords

breast cancer; CXCR4; lipocalin 2; liposome; migration; siRNA

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; IMMUNOLIPOSOME; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; LIPOSOME; MONOCLONAL ANTIBODY; ONCOPROTEIN;

ARTICLE; BREAST METASTASIS; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CYTOTOXICITY; DRUG POTENTIATION; ENCAPSULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIMIT OF QUANTITATION; MIGRATION INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUSTAINED DRUG RELEASE; TRIPLE NEGATIVE BREAST CANCER; ZETA POTENTIAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PH; SECONDARY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACUTE-PHASE PROTEINS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOCALINS; LIPOSOMES; PROTO-ONCOGENE PROTEINS; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84901741826     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4004699     Document Type: Article

References (48)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer Statistics, 2012 Ca-Cancer J. Clin. 2012, 62, 10-29
2. Perez, E. A.; Spano, J.-P. Current and Emerging Targeted Therapies for Metastatic Breast Cancer Cancer 2012, 118, 3014-3025
3. Carter, C. L.; Allen, C.; Henson, D. E. Relation of Tumor Size, Lymph Node Status, and Survival in 24,740 Breast Cancer Cases Cancer 1989, 63, 181-187
4. Vogel, C. L. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer J. Clin. Oncol. 2002, 20, 719-726
5. Geyer, C. E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C. G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S. D.; Stein, S.; Cameron, D. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer N. Engl. J. Med. 2006, 355, 2733-2743
6. Awada, A.; Dirix, L.; Manso Sanchez, L.; Xu, B.; Luu, T.; Dieras, V.; Hershman, D. L.; Agrapart, V.; Ananthakrishnan, R.; Staroslawska, E. Safety and Efficacy of Neratinib (HKI-272) plus Vinorelbine in the Treatment of Patients with ErbB2-Positive Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy Ann. Oncol. 2013, 24 (1) 109-116
7. Owens, M. A.; Horten, B. C.; Da Silva, M. M. HER2 Amplification Ratios by Fluorescence in Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues Clin. Breast Cancer 2004, 5, 63-69
8. Qian, Z. M. Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway Pharmacol. Rev. 2002, 54, 561-587
9. Zhu, Z. Targeted Cancer Therapies Based on Antibodies Directed against Epidermal Growth Factor Receptor: Status and Perspectives Acta Pharmacol. Sin. 2007, 28, 1476-1493
10. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verástegui, E.; Zlotnik, A. Involvement of Chemokine Receptors in Breast Cancer Metastasis Nature 2001, 410, 50-56
11. Wu, B.; Chien, E. Y. T.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists Science 2010, 330, 1066-1071
12. Busillo, J. M.; Benovic, J. L. Regulation of CXCR4 Signaling Biochim. Biophys. Acta, Biomembr. 2007, 1768, 952-963
13. Yang, J.; Moses, M. A. Lipocalin 2: A Multifaceted Modulator of Human Cancer Cell Cycle 2009, 8, 2347-2352
14. Bauer, M.; Eickhoff, J. C.; Gould, M. N.; Mundhenke, C.; Maass, N.; Friedl, A. Neutrophil Gelatinase-Associated Lipocalin (NGAL) Is a Predictor of Poor Prognosis in Human Primary Breast Cancer Breast Cancer Res. Treat. 2008, 108, 389-397
15. Yang, J.; Bielenberg, D. R.; Rodig, S. J.; Doiron, R.; Clifton, M. C.; Kung, A. L.; Strong, R. K.; Zurakowski, D.; Moses, M. A. Lipocalin 2 Promotes Breast Cancer Progression Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 3913-3918
16. Leng, X.; Ding, T.; Lin, H.; Wang, Y.; Hu, L.; Hu, J.; Feig, B.; Zhang, W.; Pusztai, L.; Symmans, W. F.; Wu, Y.; Arlinghaus, R. B. Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis Cancer Res. 2009, 69, 8579-8584
17. Scherr, M.; Battmer, K.; Schultheis, B.; Ganser, A.; Eder, M. Stable RNA Interference (RNAi) as an Option for Anti-Bcr-Abl Therapy Gene Ther. 2005, 12, 12-21
18. Morrissey, D. V.; Lockridge, J. A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; Vaish, N.; Zinnen, S.; Vargeese, C.; Bowman, K.; Shaffer, C. S.; Jeffs, L. B.; Judge, A.; MacLachlan, I.; Polisky, B. Potent and Persistent in Vivo Anti-HBV Activity of Chemically Modified siRNAs Nat. Biotechnol. 2005, 23, 1002-1007
19. Landen, C. N.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M. T.; Lopez-Berestein, G.; Sood, A. K. Therapeutic EphA2 Gene Targeting in Vivo Using Neutral Liposomal Small Interfering RNA Delivery Cancer Res. 2005, 65, 6910-6918
20. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.; Röhl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H.-P. Therapeutic Silencing of an Endogenous Gene by Systemic Administration of Modified siRNAs Nature 2004, 432, 173-178
21. Zhang, M.; Zhou, Y.; Xie, C.; Zhou, F.; Chen, Y.; Han, G.; Zhang, W. J. STAT6 Specific shRNA Inhibits Proliferation and Induces Apoptosis in Colon Cancer HT-29 Cells Cancer Lett. 2006, 243, 38-46
22. Gómez-Valadés, A. G.; Vidal-Alabró, A.; Molas, M.; Boada, J.; Bermúdez, J.; Bartrons, R.; Perales, J. C. Overcoming Diabetes-Induced Hyperglycemia through Inhibition of Hepatic Phosphoenolpyruvate Carboxykinase (GTP) with RNAi Mol. Ther. 2006, 13, 401-410
23. Scherr, M.; Battmer, K.; Schultheis, B.; Ganser, A.; Eder, M. Stable RNA Interference (RNAi) as an Option for Anti-Bcr-Abl Therapy Gene Ther. 2005, 12, 12-21
24. Gonzalez-Alegre, P.; Bode, N.; Davidson, B. L.; Paulson, H. L. Silencing Primary Dystonia: Lentiviral-Mediated RNA Interference Therapy for DYT1 Dystonia J. Neurosci. 2005, 25, 10502-10509
25. Mok, H. P.; Lever, A. M. L. Vector Integration: Location, Location, Location Gene Ther. 2005, 12, 1-2
26. Taulli, R.; Accornero, P.; Follenzi, A.; Mangano, T.; Morotti, A.; Scuoppo, C.; Forni, P. E.; Bersani, F.; Crepaldi, T.; Chiarle, R.; Naldini, L.; Ponzetto, C. RNAi Technology and Lentiviral Delivery as a Powerful Tool to Suppress Tpr-Met-Mediated Tumorigenesis Cancer Gene Ther. 2005, 12, 456-463
27. Rubinson, D. A.; Dillon, C. P.; Kwiatkowski, A. V.; Sievers, C.; Yang, L.; Kopinja, J.; Rooney, D. L.; Zhang, M.; Ihrig, M. M.; McManus, M. T.; Gertler, F. B.; Scott, M. L.; Van Parijs, L. A Lentivirus-Based System to Functionally Silence Genes in Primary Mammalian Cells, Stem Cells and Transgenic Mice by RNA Interference Nat. Genet. 2003, 33, 401-406
28. Zhang, C.; Tang, N.; Liu, X.; Liang, W.; Xu, W.; Torchilin, V. P. siRNA-Containing Liposomes Modified with Polyarginine Effectively Silence the Targeted Gene J. Controlled Release 2006, 112, 229-239
29. Auguste, D.; Furman, K.; Wong, A.; Fuller, J.; Armes, S.; Deming, T.; Langer, R. Triggered Release of siRNA from Poly(ethylene Glycol)-Protected, pH-Dependent Liposomes J. Controlled Release 2008, 130, 266-274
30. Epstein, R. J. The CXCL12-CXCR4 Chemotactic Pathway as a Target of Adjuvant Breast Cancer Therapies Nat. Rev. Cancer 2004, 4, 901-909
31. Salvucci, O.; Bouchard, A.; Baccarelli, A.; Deschenes, J.; Sauter, G.; Simon, R.; Bianchi, R.; Basik, M. The Role of CXCR4 Receptor Expression in Breast Cancer: A Large Tissue Microarray Study Breast Cancer Res. Treat. 2005, 97, 275-283
32. Gunawan, R. C.; Auguste, D. T. The Role of Antibody Synergy and Membrane Fluidity in the Vascular Targeting of Immunoliposomes Biomaterials 2010, 31, 900-907
33. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; Wernerus, H.; Björling, L.; Ponten, F. Towards a Knowledge-Based Human Protein Atlas Nat. Biotechnol. 2010, 28, 1248-1250
34. Uhlen, M. A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics Mol. Cell. Proteomics 2005, 4, 1920-1932
35. Pontén, F.; Jirström, K.; Uhlen, M. The Human Protein Atlas-a Tool for Pathology J. Pathol. 2008, 216, 387-393
36. Lundberg, E.; Fagerberg, L.; Klevebring, D.; Matic, I.; Geiger, T.; Cox, J.; Älgenäs, C.; Lundeberg, J.; Mann, M.; Uhlen, M. Defining the Transcriptome and Proteome in Three Functionally Different Human Cell Lines Mol. Syst. Biol. 2010, 10.1038/msb.2010.106
37. Pontén, F.; Gry, M.; Fagerberg, L.; Lundberg, E.; Asplund, A.; Berglund, L.; Oksvold, P.; Björling, E.; Hober, S.; Kampf, C.; Navani, S.; Nilsson, P.; Ottosson, J.; Persson, A.; Wernérus, H.; Wester, K.; Uhlén, M. A Global View of Protein Expression in Human Cells, Tissues, and Organs. Mol. Syst. Biol. 2009, 10.1038/msb.2009.93.
38. Guo, P.; You, J.-O.; Yang, J.; Moses, M. A.; Auguste, D. T. Using Breast Cancer Cell CXCR4 Surface Expression to Predict Liposome Binding and Cytotoxicity Biomaterials 2012, 33, 8104-8110
39. Semple, S. C.; Klimuk, S. K.; Harasym, T. O.; Dos Santos, N.; Ansell, S. M.; Wong, K. F.; Maurer, N.; Stark, H.; Cullis, P. R.; Hope, M. J.; Scherrer, P. Efficient Encapsulation of Antisense Oligonucleotides in Lipid Vesicles Using Ionizable Aminolipids: Formation of Novel Small Multilamellar Vesicle Structures Biochim. Biophys. Acta 2001, 1510, 152-166
40. You, J.-O.; Almeda, D.; Ye, G. J.; Auguste, D. T. Bioresponsive Matrices in Drug Delivery J. Biol. Eng. 2010, 4, 15
41. Hillaireau, H.; Couvreur, P. Nanocarriers' Entry into the Cell: Relevance to Drug Delivery Cell. Mol. Life Sci. 2009, 66, 2873-2896
42. Jølck, R. I.; Feldborg, L. N.; Andersen, S.; Moghimi, S. M.; Andresen, T. L. Engineering Liposomes and Nanoparticles for Biological Targeting. In Biofunctionalization of Polymers and their Applications; Nyanhongo, G. S.; Steiner, W.; Gübitz, G., Eds.; Springer Berlin Heidelberg: Berlin, Heidelberg, 2010, Vol. 125; pp 251-280.
43. Son, K. K.; Patel, D. H.; Tkach, D.; Park, A. Cationic Liposome and Plasmid DNA Complexes Formed in Serum-Free Medium under Optimum Transfection Condition Are Negatively Charged Biochim. Biophys. Acta 2000, 1466, 11-15
44. Rhodes, L. V.; Bratton, M. R.; Zhu, Y.; Tilghman, S. L.; Muir, S. E.; Salvo, V. A.; Tate, C. R.; Elliott, S.; Nephew, K. P.; Collins-Burow, B. M.; Burow, M. E. Effects of SDF-1-CXCR4 Signaling on microRNA Expression and Tumorigenesis in Estrogen Receptor-Alpha (ER-A)-Positive Breast Cancer Cells Exp. Cell Res. 2011, 317, 2573-2581
45. Wang, J.; Cai, J.; Han, F.; Yang, C.; Tong, Q.; Cao, T.; Wu, L.; Wang, Z. Silencing of CXCR4 Blocks Progression of Ovarian Cancer and Depresses Canonical Wnt Signaling Pathway Int. J. Gynecol. Cancer 2011, 21, 981-987
46. Wang, Z.; Ma, Q.; Liu, Q.; Yu, H.; Zhao, L.; Shen, S.; Yao, J. Blockade of SDF-1/CXCR4 Signalling Inhibits Pancreatic Cancer Progression in Vitro via Inactivation of Canonical Wnt Pathway Br. J. Cancer 2008, 99, 1695-1703
47. Shi, H.; Gu, Y.; Yang, J.; Xu, L.; Mi, W.; Yu, W. Lipocalin 2 Promotes Lung Metastasis of Murine Breast Cancer Cells J. Exp. Clin. Cancer Res. 2008, 27, 83
48. Teicher, B. A.; Fricker, S. P. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer Clin. Cancer Res. 2010, 16, 2927-2931